Financial Highlights
| 12/2023 | 12/2022※ | |
|---|---|---|
| For the year: | (Millions of yen) | |
| Net sales | ¥54,638 | ¥48,896 |
| Operating income | 5,035 | 5,540 |
| Income before income taxes | 5,593 | 5,722 |
| Net income | 4,119 | 3,944 |
| At year-end: | ||
| Total assets | 133,432 | 133,689 |
| Total equity | 120,134 | 119,224 |
| Per share data: | (yen) | |
| Net income | ¥146.60 | ¥140.39 |
| Cash dividends | 120.0 | 100.0 |
※The " Accounting Standard for Revenue Recognition " (ASBJ Statement No. 29, March 31, 2020) etc. have been applied from the beginning of the fiscal year ended December 31, 2022.
Net Sales
Ordinary Income
Net Income
※Includes income from the termination of the exclusive rights to market the six anti-HIV drugs in Japan
Total equity
